NEOS Investment Management LLC Acquires 2,894 Shares of Biogen Inc. $BIIB

NEOS Investment Management LLC lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 13.9% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 23,734 shares of the biotechnology company’s stock after buying an additional 2,894 shares during the quarter. NEOS Investment Management LLC’s holdings in Biogen were worth $5,128,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of BIIB. BlackRock Inc. acquired a new stake in Biogen in the second quarter worth $3,453,878,000. Primecap Management Co. CA acquired a new position in shares of Biogen during the second quarter valued at about $3,274,304,000. Geode Capital Management LLC raised its holdings in shares of Biogen by 3.2% during the fourth quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock valued at $736,435,000 after purchasing an additional 130,618 shares during the period. Wellington Management Group LLP boosted its position in shares of Biogen by 5.3% during the 2nd quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock worth $673,560,000 after purchasing an additional 155,828 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Biogen during the 4th quarter worth about $464,408,000. Institutional investors own 87.93% of the company’s stock.

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $220.83 on Monday. The business’s 50 day moving average is $209.53 and its 200 day moving average is $196.62. Biogen Inc. has a 12-month low of $135.39 and a 12-month high of $225.80. The stock has a market cap of $32.63 billion, a price-to-earnings ratio of 39.08, a PEG ratio of 2.44 and a beta of 0.17. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The business had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.46 billion. During the same period in the prior year, the firm posted $5.47 EPS. Biogen’s quarterly revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, sell-side analysts forecast that Biogen Inc. will post 12.39 earnings per share for the current fiscal year.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Long-term Dravet syndrome data support zorevunersen. Biogen and Stoke Therapeutics reported four-year Phase 1/2a extension data showing durable seizure reductions, including reductions in severe seizure types associated with sudden unexpected death in epilepsy, as well as continued improvements in cognition, behavior and quality of life. The results strengthen the potential for zorevunersen to become a disease-modifying treatment, though it remains investigational. Stoke and Biogen unveil long-term zorevunersen data
• Positive Sentiment: LEQEMBI gained a major China regulatory approval. China’s National Medical Products Administration approved the once-weekly subcutaneous autoinjector formulation of LEQEMBI for initiation treatment in early Alzheimer’s disease. At-home dosing could improve patient convenience, reduce infusion-center burdens and broaden adoption in a large and growing market. Eisai leads development and commercialization, with Biogen sharing economics under their collaboration. Biogen and Eisai announce China LEQEMBI approval
• Positive Sentiment: U.S. patients can now access weekly at-home LEQEMBI injections. Biogen and Eisai launched LEQEMBI IQLIK in the United States for eligible early Alzheimer’s patients, offering initiation and maintenance treatment through a pre-filled syringe or autoinjector. The new delivery option may lower barriers to treatment and support future product demand.
• Neutral Sentiment: Investors are assessing valuation after a strong rally. A valuation analysis argued that BIIB could be materially below estimated discounted-cash-flow value, but also noted that earnings-based multiples make the shares appear expensive. This conflicting signal may be contributing to caution after the stock’s substantial one-year gain.
• Negative Sentiment: Execution and safety risks remain. Zorevunersen’s data are from open-label early-stage studies and require confirmation in later trials. LEQEMBI’s subcutaneous formulation also carries injection-related reactions and still requires MRI monitoring for amyloid-related imaging abnormalities, potentially limiting uptake.

Analyst Ratings Changes

A number of analysts recently commented on BIIB shares. Wolfe Research raised Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 target price for the company in a research report on Thursday, August 13th. Truist Financial upgraded Biogen from a “hold” rating to a “buy” rating and increased their price target for the stock from $190.00 to $235.00 in a report on Monday, July 13th. Mizuho raised their price objective on Biogen from $221.00 to $241.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. Wedbush boosted their price objective on Biogen from $201.00 to $215.00 and gave the company a “neutral” rating in a report on Thursday, July 30th. Finally, Morgan Stanley increased their target price on Biogen from $222.00 to $231.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $228.50.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.